

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081766 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
A61K 47/68 (2017.01) C07K 16/18 (2006.01)
A61K 38/07 (2006.01) C12N 15/10 (2006.01)

(21) International Application Number:

PCT/US2022/079232

(22) International Filing Date:

03 November 2022 (03.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/275,346 03 November 2021 (03.11.2021) US

(71) Applicants: **RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY** [US/US]; 83 Somerset Street, New Brunswick, New Jersey 08901 (US). **MBRACE THERAPEUTICS, INC.** [US/US]; 4660 La Jolla Village Drive, Suite 950, San Diego, California 92121 (US).

(72) Inventors: **PASQUALINI, Renata**; c/o Rutgers University, 205 South Orange Avenue, Newark, New Jersey 07103 (US). **ARAP, Wadih**; c/o Rutgers University, 185 South Orange Avenue, Newark, New Jersey 07103 (US). **STAQUICINI, Fernanda I.**; 556 Morris Avenue, Building S7-F3, Summit, New Jersey 07901 (US).

(74) Agent: **SILVA, Domingos J.** et al.; Saul Ewing Arnstein & Lehr LLP, Centre Square West, 1500 Market Street, 38th Floor, Philadelphia, Pennsylvania 19102 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

15 June 2023 (15.06.2023)

(54) Title: ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5




FIG. 115A

(57) Abstract: The present invention relates in certain aspects to antibodies, binding polypeptides, and immunoconjugates specific for human EPH receptor A5 (EphA5).

WO 2023/081766 A3